The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.
 
Maria Diab
No Relationships to Disclose
 
Subir Goyal
No Relationships to Disclose
 
Jeffrey M. Switchenko
No Relationships to Disclose
 
Olatunji B. Alese
Consulting or Advisory Role - Ipsen; Natera; Pathema GX; Pfizer; QED Therapeutics; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corcept Therapeutics (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); MabSpace Biosciences (Inst); PCI Biotech (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Walid Labib Shaib
Honoraria - Blueprint Medicines; BMS; Ipsen; Lexicon; Mylan; Natera
Research Funding - ArQule (Inst); Basilea (Inst); GlaxoSmithKline (Inst); Lexicon (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Lexicon
 
Mehmet Akce
Consulting or Advisory Role - Eisai; Exelixis; GlaxoSmithKline; Ipsen; QED Therapeutics
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Tesaro (Inst); Xencor (Inst)
 
Christina Wu
Honoraria - Oncology Learning Network; PrecisCA
Consulting or Advisory Role - Array BioPHarma; Natera; Nova Research Company
Research Funding - Boston Biomedical (Inst); InhibRx (Inst); Lycera (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Bassel F. El-Rayes
Honoraria - Charles River Associates
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Exelixis; Genentech; QED Therapeutics; QED Therapeutics; Seagen; Stemline Therapeutics; Taiho Oncology; Taiho Oncology
Speakers' Bureau - Intellisphere
Research Funding - Adaptimmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); IQvia (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Wayne State University (Inst); Xencor (Inst); Zymeworks (Inst)
Other Relationship - ERYTECH Pharma; Exelixis; SC Liver Research Consortium